Literature DB >> 7365315

Effects of propranolol on aldosterone plasma concentration and aldosterone metabolic clearance in hypertensive patients.

J H Pratt, C E Grim, C A Parkinson.   

Abstract

Although propranolol administration produces a lowering of PRA, PAC does not decrease in a similar fashion. In the present study the effects of propranolol on the aldosterone MCR were examined. Eight patients with essential hypertension were studied while receiving treatment with a diuretic and again after propranolol (160 to 320 mg/day) was added to the therapeutic regimen. Propranolol therapy was associated with a 25% decrease in PRA (p less than 0.05) and changes in PACs that were variable but not significantly different from diuretic therapy alone. The aldosterone MCR decreased from 1420 +/- 120 to 1120 +/- 90 L/24 hr in response to propranolol (p less than 0.01). The average production rate of aldosterone (MCR X PAC) did not change after propranolol treatment despite a decrease in PRA. There were no changes in plasma concentrations of potassium or in ACTH secretion (as reflected by levels of cortisol) to explain a role for propranolol to sustain aldosterone secretion. Thus propranolol administered to hypertensive patients pretreated with a diuretic can affect circulating levels of aldosterone apart from changes in PRA. Propranolol therapy produces a moderate reduction in aldosterone MCR and appears to augment aldosterone production by a mechanism exclusive of known stimuli.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7365315

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  2 in total

1.  Effect of propranolol on noradrenaline kinetics in patients with essential hypertension.

Authors:  M Esler; G Jackman; P Leonard; H Skews; A Bobik; G Jennings
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

2.  Propranolol enhances the effect of ACTH on plasma cortisol, but not on aldosterone in man.

Authors:  L Belkien; J Baumann; M Schirpai; W Oelkers
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.